Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations

Isaacs, Randi and Chen, Xueying and Graus Porta, Diana and Parker, Katie and Yu, Kun and Porter, Dale (2018) Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer discovery. ISSN 2159-8290; 2159-8274

Abstract

We report the activity of BGJ398, a potent and selective pan-fibroblast growth factor receptor (FGFR) antagonist, in patients with metastatic urothelial carcinoma bearing relevant genomic alterations. Patients (N = 67) who had received prior platinum chemotherapy with a diverse array of FGFR3 alterations were enrolled. The majority (70.1%) had ≥2 prior antineoplastic therapies. BGJ398 was administered at 125 mg oral daily on a 3 week on, 1 week off schedule until the time of unacceptable toxicity or progression. The primary endpoint was response rate (RR). Amongst 67 evaluable patients, an overall RR of 25.4% was observed and an additional 39% of patients had disease stabilization, translating to a clinical benefit rate of 64.2%. The most common treatment-emergent toxicities encountered with therapy included hyperphosphatemia, elevated creatinine, fatigue and constipation. Further examination of BGJ398 in this disease setting is therefore warranted.

Item Type: Article
Date Deposited: 06 Jul 2018 00:45
Last Modified: 06 Jul 2018 00:45
URI: https://oak.novartis.com/id/eprint/34650

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.